Blog

Archive October 2020

All of the articles archived for the month that you have specified are displayed below.

ASNC2020 Finale: University of Rochester Imaging ‘Aces’ Zoom in on Hot Topics

Presenting live from the University of Rochester Medical Center, Ronald G. Schwartz, MD, MS, MASNC, Maria L. Mackin, MS, CNMT, RT(N), LNMT, Jesse A. Doran, MD, Hima Vidula, MD, and Erin M. Armenia, MD, delivered the grand finale to ASNC's 25th Annual Scientific Session on Wednesday, Oct. 7. 

ASNC President-elect Dr. Randall Thompson Highlights 'Reasons to Be Optimistic'

In ASNC's 25th Annual Scientific Session welcome plenary, the Society's president-elect, Randall C. Thompson, MD, FASNC, shared highlights of his journey as a nuclear cardiologist. He noted mentors and colleagues he has met along the way, and shared tales of global adventures experienced while traveling the globe to perform CT scans on mummies, apes, and tribesmen. 

Putting It All Together: Rush/Cook County Team Shows Value of Ancillary Data in Case Interpretation

After winning praise from around the world for its jam-packed Main Event, ASNC2020 returned on Sept. 30 with a Cases with the Aces session featuring faculty from Rush University Medical Center and Cook County Health. Together Rami Doukky, MD, FASNC, Rupa Mehta Sanghani, MD, FASNC, and Brian Clark, MD, presented nine cases, each including PET or SPECT images, clinical and ancillary data, as well as technical considerations.    

PET Tracers in Cardiac Amyloidosis

Guest Bloggers: Pranav Chandrashekar, MD; Ahmad Masri, MD MS, The Amyloidosis Center, Knight Cardiovascular Institute, Oregon Health & Science University 
----- Molecular Basis of PET Imaging in Cardiac Amyloidosis------In the last 5 years, nuclear cardiology revolutionized our approach to cardiac amyloidosis (CA). Characterized by amyloid protein deposition in the extracellular space, CA is well suited to be imaged by molecular imaging techniques. While there are many types of amyloidosis, the two most common types affecting the heart are light chain cardiac amyloidosis (AL-CA) and transthyretin cardiac amyloidosis (ATTR-CA). The introduction of different molecular probes has expanded the potential applications of molecular imaging techniques in CA well beyond disease diagnosis extending to treatment monitoring and prognosis.

Call to Action: This Is Our Chance to Fix Pennsylvania's Flawed Act 112

Work on modifying PA Act 112, "The Patient Test Result Information Act" is ongoing. This Pennsylvania law requires any entity performing a diagnostic imaging service to notify the patient (or patient's designee) within 20 days when “significant abnormalities may exist." This law includes nuclear cardiology and molecular imaging. 

 

Advocacy Alert: ASNC Urges CMS to Stop Cut to Proposed Conversion Factor

ASNC has commented to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to the Medicare Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System for 2021.

ASNC Addressing CT Coverage Policy Issues with Humana, United Healthcare

ASNC is moving quickly to resolve two issues that have arisen around insurers’ activity around CT coverage. 

Reducing Radiation Dose in Nuclear Cardiology

Guest Blogger: Thomas H. Hauser, MD, MPH, MMSc, @ThomasHauser_MD, member of the ASNC Social Media Task Force---
Nuclear cardiology studies play a key role in the diagnosis of heart disease, the determination of prognosis, and the appropriate management of patients.  Although these benefits are clear, we must also be mindful of the potential downsides associated with these studies, including the use of ionizing radiation.

24/7/365 Education: ASNC2020 Meeting OnDemand to Be Released Soon

ASNC2020 All-Access Passholders will receive 12 months of unlimited Meeting OnDemand. 

Contributors